Ryota Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryota Nakamura has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Nobutaka Hattori
Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo 113-8421, Japan
3 shared publications - Shin-Ichi Ueno
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
2 shared publications - Takao Urabe
Department of Neurology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan
2 shared publications - Asako Yoritaka
Department of Neurology, Juntendo University Koshigaya Hospital, Saitama, Japan
1 shared publication - Douglas Kazutoshi Sato
School of Medicine and Institute for Geriatrics and Gerontology, Pontifical Catholic University of Rio Grande do Sul, Av. Ipiranga, 6681, Porto Alegre, Brazil
1 shared publication - Eriko Kado
Department of Neurology, Juntendo University Urayasu Hospital, Urayasu, Japan
1 shared publication
Latest Publications
- Open Access
- 17 May 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 461, 123051
Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study
- 17 May 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 461, 123051
Open AccessSafinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study
- Open Access
- 20 November 2021
- Published by Elsevier in eNeurologicalSci
- Vol. 25, 100381
An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
- 20 November 2021
- Published by Elsevier in eNeurologicalSci
- Vol. 25, 100381
Open AccessAn 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination
- Open Access
- 30 November 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 224
Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report
Myelin-oligodendrocyte glycoprotein antibody (MOG antibodies) was found in various demyelinated diseases. This is the first report of a patient with longitudinally extensive transverse myelitis with an extremely high titer of MOG antibodies after an influenza infection. This case supports the view that MOG antibodies are linked to longitudinally extensive transverse myelitis and that influenza infection might trigger the MOG antibodies. A 32-year-old healthy male developed high fever, dysesthesia and paraesthesia below the C2 area, muscle weakness of the bilateral lower extremities, and urinary retention ten days after an influenza type A infection. Magnetic resonance imaging revealed a longitudinal lesion in the spinal cord extending from C2 to the spinal conus. There were no lesions in the brain or optic nerves. Established cell-based immunoassays revealed that he was positive for MOG antibodies (titer = 65,536) and negative for anti-aquaporin 4 antibodies (AQP4 antibodies). He fully recovered after steroid pulse therapy followed by 60 mg prednisolone. This is the first report of influenza A-associated longitudinally extensive transverse myelitis with a high titer anti-MOG antibodies. Our case report supports a relationship between anti-MOG antibodies and longitudinally extensive transverse myelitis, which was triggered by influenza infection. Further studies are needed to establish the clinical significance of anti-MOG antibodies for diagnosis, treatment, and prognosis.
- 30 November 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 224
Open AccessInfluenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report
Myelin-oligodendrocyte glycoprotein antibody (MOG antibodies) was found in various demyelinated diseases. This is the first report of a patient with longitudinally extensive transverse myelitis with an extremely high titer of MOG antibodies after an influenza infection. This case supports the view that MOG antibodies are linked to longitudinally extensive transverse myelitis and that influenza infection might trigger the MOG antibodies. A 32-year-old healthy male developed high fever, dysesthesia and paraesthesia below the C2 area, muscle weakness of the bilateral lower extremities, and urinary retention ten days after an influenza type A infection. Magnetic resonance imaging revealed a longitudinal lesion in the spinal cord extending from C2 to the spinal conus. There were no lesions in the brain or optic nerves. Established cell-based immunoassays revealed that he was positive for MOG antibodies (titer = 65,536) and negative for anti-aquaporin 4 antibodies (AQP4 antibodies). He fully recovered after steroid pulse therapy followed by 60 mg prednisolone. This is the first report of influenza A-associated longitudinally extensive transverse myelitis with a high titer anti-MOG antibodies. Our case report supports a relationship between anti-MOG antibodies and longitudinally extensive transverse myelitis, which was triggered by influenza infection. Further studies are needed to establish the clinical significance of anti-MOG antibodies for diagnosis, treatment, and prognosis.